drugset
drugset / Trial / NCT00517361

Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer

NCT00517361 ↗

Phase 2 Terminated 11 enrolled University of Chicago Genentech, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the progression free survival (PFS) of metastatic ER, PR and HER2/neu negative breast cancers to the combination of carboplatin and bevacizumab (Avastin®) therapy.

Timeline

Start
2007-08
Primary completion
2011-04
Completion
2012-04

Outcome

Outcome not reported

Stopped (Enrollment): “This study has been terminated due to poor accrual”

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 15 mg/kg Intravenous
Subject Carboplatin Small molecule 6 unknown Intravenous

Indications

breast cancer